CTIC insider filings

CTI BIOPHARMA CORP — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2023-06-28. Screen CTIC transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for CTIC between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.

Recent insider filings — CTI BIOPHARMA CORP

FiledFormInsiderReported transactionsSource
2023-06-284BVF PARTNERS L P/IL — Director, 10% owner
BIOTECHNOLOGY VALUE FUND L P — Director, 10% owner
BVF I GP LLC — Director, 10% owner
BIOTECHNOLOGY VALUE FUND II LP — Director
BVF II GP LLC — Director
Biotechnology Value Trading Fund OS LP — Director
BVF Partners OS Ltd. — Director
BVF GP HOLDINGS LLC — Director, 10% owner
BVF INC/IL — Director, 10% owner
LAMPERT MARK N — Director, 10% owner
Code (U): 3,989,130 @ $9.10 · Code (U): 2,595,239 @ $9.10 · Code (U): 702,505 @ $9.10 · Code (U): 1,526,147 @ $9.10 · Code (U): 43,139 @ $9.10 · Code (U): 1,594 (derivative) · +12 moreEDGAR
2023-06-264Fong James K — EVP & Chief Commercial OfficerCode (U): 3,565 @ $9.10 · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 8,250 (derivative) · Disposition to issuer (D): 58,750 (derivative) · Disposition to issuer (D): 23,340 (derivative) · Disposition to issuer (D): 188,000 (derivative) · +4 moreEDGAR
2023-06-264Parks Diane L. — DirectorDisposition to issuer (D): 120,000 (derivative) · Disposition to issuer (D): 80,000 (derivative) · Disposition to issuer (D): 80,000 (derivative)EDGAR
2023-06-264Tuckson Reed Vaughn — DirectorCode (U): 48,639 @ $9.10 · Disposition to issuer (D): 50,000 (derivative) · Disposition to issuer (D): 60,000 (derivative) · Disposition to issuer (D): 120,000 (derivative) · Disposition to issuer (D): 126,000 (derivative) · Disposition to issuer (D): 80,000 (derivative) · +2 moreEDGAR
2023-06-264Metzger Michael A — DirectorDisposition to issuer (D): 50,000 (derivative) · Disposition to issuer (D): 60,000 (derivative) · Disposition to issuer (D): 63,000 (derivative) · Disposition to issuer (D): 80,000 (derivative) · Disposition to issuer (D): 80,000 (derivative) · Disposition to issuer (D): 80,000 (derivative)EDGAR
2023-06-264PERRY MATTHEW D — DirectorCode (U): 43,139 @ $9.10 · Disposition to issuer (D): 50,000 (derivative) · Disposition to issuer (D): 60,000 (derivative) · Disposition to issuer (D): 120,000 (derivative) · Disposition to issuer (D): 80,000 (derivative) · Disposition to issuer (D): 80,000 (derivative) · +1 moreEDGAR
2023-06-264Parkinson David Ross — DirectorDisposition to issuer (D): 50,000 (derivative) · Disposition to issuer (D): 60,000 (derivative) · Disposition to issuer (D): 120,000 (derivative) · Disposition to issuer (D): 126,000 (derivative) · Disposition to issuer (D): 80,000 (derivative) · Disposition to issuer (D): 80,000 (derivative) · +1 moreEDGAR
2023-06-264Fischer Laurent — DirectorDisposition to issuer (D): 50,000 (derivative) · Disposition to issuer (D): 60,000 (derivative) · Disposition to issuer (D): 120,000 (derivative) · Disposition to issuer (D): 126,000 (derivative) · Disposition to issuer (D): 80,000 (derivative) · Disposition to issuer (D): 80,000 (derivative) · +1 moreEDGAR
2023-06-264Craig Adam R — President and CEO, DirectorCode (U): 31,470 @ $9.10 · Disposition to issuer (D): 1,200,000 (derivative) · Disposition to issuer (D): 450,000 (derivative) · Disposition to issuer (D): 475,000 (derivative) · Disposition to issuer (D): 600,000 (derivative) · Disposition to issuer (D): 470,054 (derivative) · +4 moreEDGAR
2023-06-264KIRSKE DAVID — EVP, Chief Financial OfficerCode (U): 17,547 @ $9.10 · Disposition to issuer (D): 25,000 (derivative) · Disposition to issuer (D): 315,000 (derivative) · Disposition to issuer (D): 83,396 (derivative) · Disposition to issuer (D): 270,216 (derivative) · Disposition to issuer (D): 340,000 (derivative) · +3 moreEDGAR
2023-04-074Parks Diane L. — DirectorGrant/award (A): 80,000 (derivative) @ $0EDGAR
2023-04-074Tuckson Reed Vaughn — DirectorGrant/award (A): 80,000 (derivative) @ $0EDGAR
2023-04-074Metzger Michael A — DirectorGrant/award (A): 80,000 (derivative) @ $0EDGAR
2023-04-074PERRY MATTHEW D — DirectorGrant/award (A): 80,000 (derivative) @ $0EDGAR
2023-04-074Parkinson David Ross — DirectorGrant/award (A): 80,000 (derivative) @ $0EDGAR
2023-04-074Fischer Laurent — DirectorGrant/award (A): 80,000 (derivative) @ $0EDGAR
2023-04-074BVF PARTNERS L P/IL — Director, 10% owner
BIOTECHNOLOGY VALUE FUND L P — Director, 10% owner
BVF I GP LLC — Director, 10% owner
BIOTECHNOLOGY VALUE FUND II LP — Director
BVF II GP LLC — Director
Biotechnology Value Trading Fund OS LP — Director
BVF Partners OS Ltd. — Director
BVF GP HOLDINGS LLC — Director, 10% owner
BVF INC/IL — Director, 10% owner
LAMPERT MARK N — Director, 10% owner
Grant/award (A): 80,000 (derivative) @ $0EDGAR
2023-03-164Fong James K — EVP & Chief Commercial OfficerGrant/award (A): 200,000 (derivative) @ $0EDGAR
2023-03-164Craig Adam R — President and CEO, DirectorGrant/award (A): 900,000 (derivative) @ $0EDGAR
2023-03-164KIRSKE DAVID — EVP, Chief Financial OfficerGrant/award (A): 200,000 (derivative) @ $0EDGAR
2023-01-264Fong James K — EVP & Chief Commercial OfficerOption exercise (M): 100,000 @ $0.95 · Sale (S): 100,000 @ $6 · Grant/award (A): 288,000 (derivative) @ $0 · Option exercise (M): 100,000 (derivative) @ $0EDGAR
2023-01-264Craig Adam R — President and CEO, DirectorOption exercise (M): 83,200 @ $0.84 · Sale (S): 83,200 @ $6 · Option exercise (M): 2,117 @ $0.84 · Sale (S): 2,117 @ $6.01 · Option exercise (M): 83,200 (derivative) @ $0 · Option exercise (M): 2,117 (derivative) @ $0EDGAR
2023-01-034Craig Adam R — President and CEO, DirectorOption exercise (M): 13,800 @ $0.84 · Sale (S): 13,800 @ $6 · Grant/award (A): 1,579 @ $5.11 · Option exercise (M): 12,000 @ $0.84 · Sale (S): 12,000 @ $6 · Option exercise (M): 700 @ $0.84 · +10 moreEDGAR
2023-01-034KIRSKE DAVID — EVP, Chief Financial OfficerOption exercise (M): 13,174 @ $0.95 · Sale (S): 13,174 @ $6 · Grant/award (A): 214 @ $5.11 · Option exercise (M): 12,000 @ $0.95 · Sale (S): 12,000 @ $6 · Option exercise (M): 800 @ $0.95 · +10 moreEDGAR
2022-11-144Craig Adam R — President and CEO, DirectorOption exercise (M): 53,996 @ $0.84 · Sale (S): 46,100 @ $6 · Sale (S): 7,596 @ $6.01 · Sale (S): 300 @ $6.01 · Option exercise (M): 188,304 @ $0.84 · Sale (S): 136,408 @ $6 · +8 moreEDGAR
2022-11-104Metzger Michael A — DirectorOption exercise (M): 28,500 @ $0.84 · Option exercise (M): 63,000 @ $1 · Sale (S): 50,058 @ $5.53 · Sale (S): 36,942 @ $5.65 · Sale (S): 4,500 @ $5.70 · Option exercise (M): 28,500 (derivative) @ $0 · +1 moreEDGAR
2022-10-064KIRSKE DAVID — EVP, Chief Financial OfficerOption exercise (M): 1,400 @ $0.95 · Sale (S): 1,400 @ $6.25 · Option exercise (M): 100 @ $0.95 · Sale (S): 100 @ $6.26 · Option exercise (M): 609 @ $0.95 · Sale (S): 609 @ $6.27 · +3 moreEDGAR
2022-10-034KIRSKE DAVID — EVP, Chief Financial OfficerOption exercise (M): 800 @ $0.95 · Sale (S): 800 @ $6 · Option exercise (M): 100 @ $0.95 · Sale (S): 100 @ $6.01 · Option exercise (M): 139,841 @ $0.95 · Sale (S): 139,841 @ $6.05 · +6 moreEDGAR
2022-09-204KIRSKE DAVID — EVP, Chief Financial OfficerGrant/award (A): 9,516 @ $2.12 · Option exercise (M): 22,592 @ $0.95 · Sale (S): 22,592 @ $6.02 · Option exercise (M): 22,592 (derivative) @ $0EDGAR
2022-09-144Craig Adam R — President and CEO, DirectorOption exercise (M): 242,300 @ $0.84 · Sale (S): 242,300 @ $6.43 · Option exercise (M): 242,300 (derivative) @ $0EDGAR
2022-08-164Craig Adam R — President and CEO, DirectorPurchase (P): 5,000 @ $5.50EDGAR
2022-08-114BVF PARTNERS L P/IL — Director, 10% owner
BIOTECHNOLOGY VALUE FUND L P — Director, 10% owner
BVF I GP LLC — Director, 10% owner
BIOTECHNOLOGY VALUE FUND II LP — Director
BVF II GP LLC — Director
Biotechnology Value Trading Fund OS LP — Director
BVF Partners OS Ltd. — Director
BVF GP HOLDINGS LLC — Director, 10% owner
BVF INC/IL — Director, 10% owner
LAMPERT MARK N — Director, 10% owner
Sale (S): 3,850,803 @ $6.12 · Conversion (C): 3,754,000 · Sale (S): 2,890,723 @ $6.12 · Conversion (C): 2,426,666 · Sale (S): 469,040 @ $6.12 · Conversion (C): 682,666 · +6 moreEDGAR
2022-07-114Metzger Michael A — DirectorSale (S): 9,000 @ $6.50 · Sale (S): 5,900 @ $6.51 · Sale (S): 3,321 @ $6.52 · Sale (S): 400 @ $6.53 · Sale (S): 400 @ $6.54 · Sale (S): 1,100 @ $6.55EDGAR
2022-07-074Metzger Michael A — DirectorOption exercise (M): 91,500 @ $0.84 · Sale (S): 8,700 @ $5.98 · Sale (S): 51,963 @ $6.05 · Sale (S): 27,506 @ $6.14 · Sale (S): 3,331 @ $6.23 · Option exercise (M): 91,500 (derivative) @ $0EDGAR
2022-07-064Craig Adam R — President and CEO, DirectorGrant/award (A): 6,183 @ $2.12 · Option exercise (M): 27,000 @ $0.84 · Sale (S): 27,000 @ $6 · Option exercise (M): 27,000 @ $0.84 · Sale (S): 27,000 @ $6 · Option exercise (M): 18,223 @ $0.84 · +4 moreEDGAR
2022-06-174KIRSKE DAVID — EVP, Chief Financial OfficerOption exercise (M): 10,000 @ $1 · Sale (S): 10,000 @ $6 · Option exercise (M): 50,000 @ $3.30 · Sale (S): 50,000 @ $6.25 · Option exercise (M): 10,000 (derivative) @ $0 · Option exercise (M): 50,000 (derivative) @ $0EDGAR
2022-06-164KIRSKE DAVID — EVP, Chief Financial OfficerOption exercise (M): 10,000 @ $0.95 · Sale (S): 10,000 @ $5.50 · Option exercise (M): 10,000 (derivative) @ $0EDGAR
2022-06-034Craig Adam R — President and CEO, DirectorOption exercise (M): 27,000 @ $0.84 · Sale (S): 27,000 @ $6 · Option exercise (M): 27,000 @ $0.84 · Sale (S): 27,000 @ $6 · Option exercise (M): 18,223 @ $0.84 · Sale (S): 18,223 @ $6.01 · +3 moreEDGAR
2022-06-034/ACraig Adam R — President and CEO, DirectorOption exercise (M): 27,000 (derivative) @ $0 · Option exercise (M): 27,000 (derivative) @ $0 · Option exercise (M): 18,223 (derivative) @ $0EDGAR
2022-03-114Parks Diane L. — DirectorGrant/award (A): 80,000 (derivative) @ $0EDGAR
2022-03-114Tuckson Reed Vaughn — DirectorGrant/award (A): 80,000 (derivative) @ $0EDGAR
2022-03-114Metzger Michael A — DirectorGrant/award (A): 80,000 (derivative) @ $0EDGAR
2022-03-114SEELEY BRUCE J. — EVP, Chief Operating OfficerGrant/award (A): 3,164 @ $2.12 · Grant/award (A): 3,241 @ $2.11 · Grant/award (A): 280,000 (derivative) @ $0EDGAR
2022-03-114PERRY MATTHEW D — DirectorGrant/award (A): 80,000 (derivative) @ $0EDGAR
2022-03-114Parkinson David Ross — DirectorGrant/award (A): 80,000 (derivative) @ $0EDGAR
2022-03-114Fischer Laurent — DirectorGrant/award (A): 80,000 (derivative) @ $0EDGAR
2022-03-114Craig Adam R — President and CEO, DirectorGrant/award (A): 3,178 @ $2.11 · Grant/award (A): 1,115,000 (derivative) @ $0EDGAR
2022-03-114KIRSKE DAVID — EVP, Chief Financial OfficerGrant/award (A): 1,782 @ $2.12 · Grant/award (A): 1,817 @ $2.11 · Grant/award (A): 280,000 (derivative) @ $0EDGAR
2022-03-114BVF PARTNERS L P/IL — Director, 10% owner
BIOTECHNOLOGY VALUE FUND L P — 10% owner
BVF I GP LLC — 10% owner
BIOTECHNOLOGY VALUE FUND II LP
BVF II GP LLC
Biotechnology Value Trading Fund OS LP
BVF Partners OS Ltd.
BVF GP HOLDINGS LLC — 10% owner
BVF INC/IL — 10% owner
LAMPERT MARK N — 10% owner
Grant/award (A): 80,000 (derivative) @ $0EDGAR
2021-12-024Craig Adam R — President and CEO, DirectorGrant/award (A): 5,000 @ $2.12 · Purchase (P): 1,322 @ $1.52 · Purchase (P): 2,178 @ $1.52EDGAR

Recent 8-K events — CTI BIOPHARMA CORP

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2023-06-268-K1.02 — Termination of a Material Definitive Agreement
2.01 — Completion of Acquisition or Disposition of Assets
2.04 — Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
3.03 — Material Modification to Rights of Security Holders
5.01 — Changes in Control of Registrant
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
9.01 — Financial Statements and Exhibits
EDGAR
2023-05-308-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2023-05-108-K1.01 — Entry into a Material Definitive Agreement
5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2023-03-068-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2022-11-078-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2022-10-138-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersEDGAR
2022-09-288-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2022-08-158-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2022-08-088-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2022-06-038-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
5.07 — Submission of Matters to a Vote of Security Holders
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=CTIC returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs